Context: Oxidative stress is implicated in the development of vascular disease and is associated with an upregulation of vascular endothelial growth factor (VEGF), which is pathogenetically linked to the microvascular complications of diabetes. Patients of African origin have an increased susceptibility to microvascular kidney disease compared with white patients; the reasons and mechanisms that contribute to this vulnerability are unclear.
D
iabetes mellitus affects more than 415 million individuals worldwide (1) , with the most common form being type 2 diabetes mellitus (T2DM). The degree and duration of exposure to hyperglycemia is central to the development of vascular complications, including diabetic kidney disease. This complication has a predilection for patients of African descent compared with those of white origin and is the leading cause of end-stage renal disease (ESRD) (2) . The incidence of ESRD-related diabetes is four to six times higher in patients of African descent compared with whites (3) .
Persistent hyperglycemia gives rise to the accumulation of advanced glycation end-product proteins and reactive oxygen species that, together with their deficient disposal, cause a metabolic imbalance known as oxidative stress (4, 5) . In diabetic conditions, lipid hydroperoxide (LOOH) levels and histological damage of increased oxidative stress is increased in the kidney of animal models and can be reduced by antioxidant therapy (6, 7) . The mechanisms related to free radical exposure that gives rise to tissue damage involves induction of proinflammatory pathways and cytokine release (8, 9) .
Reactive oxygen species upregulate vascular endothelial growth factor (VEGF) expression in various cell types, such as endothelial cells, smooth muscle cells, and macrophages (10, 11) . Hohenstein et al. (2006) reported increased VEGF expression by many different cell types in diabetic glomeruli compared with controls (12) . VEGF increases the transcapillary leak of albumin and therefore may contribute to microvascular disease; however, it is unknown if this mechanism is relevant to the enhanced risk of nephropathy seen in certain subgroups of patients with diabetes.
Meta-analysis studies showed that VEGF genetic polymorphisms are associated with an increased risk of diabetic nephropathy in Asian and white patients (13, 14) . We have previously reported ethnic differences in VEGF +405 polymorphism in patients with diabetes that has been shown to influence circulating levels of the cytokine (15) . However, a genome-wide analysis has not shown consistent relationships between VEGF polymorphisms and circulating protein in different populations, suggesting that other nonheritable, modulating factors contribute to differences in circulating levels (16) . We reported increased oxidative stress in AfricanCaribbean patients with T2DM compared with white patients as assessed by lipid peroxidation product, antioxidant nutrients, and antioxidant enzyme activities (17) (18) (19) . Therefore, we investigated the relationship of markers of oxidative stress and VEGF production in patients with T2DM from different ethnic backgrounds.
Methods
We studied 52 patients with T2DM who were part of the Prospective Evaluation of Early Nephropathy and its Treatment (PREVENT) study. Patients were considered to be of AfricanCaribbean origin if both parents were native to either African or Caribbean countries. White patients were native to Western European or Mediterranean countries.
Individuals with a history of cardiovascular disease, defined as having a clinical record of ischemic heart disease (angina, myocardial infarction, coronary artery revascularization, and/or heart failure), peripheral vascular disease (intermittent claudication or peripheral artery revascularization) or cerebrovascular disease (transient ischemic episodes or stroke), a history of malignancy or any other life-threatening illness, current pregnancy, clinical proteinuria (albumin:creatinine ratio .30 mg/mmol), or intercurrent illness, were excluded. Microalbuminuria was diagnosed if albumin:creatinine ratio was $3 and ,30 mg/mmol in at least two of three sterile, early-morning urine samples. Therapeutic regimens for hypertension, glucose lowering, and smoking history (as either current/ex-smoker or nonsmoker) were recorded. The study was approved by the ethics committee of the Whittington Hospital Trust, and all patients provided written, informed consent.
Patients were studied in the postprandial state after a 12-hour fast. Body mass index (BMI) was calculated from weight in kilograms divided by height in square meters. Sitting blood pressure was measured after 10 minutes rest using a validated automated machine (OMRON 705HEM CP; OMRON Health Care, West Sussex, UK) using an appropriate cuff size. Venous blood was taken from an antecubital vein. Glycosylated hemoglobin A1c was measured by an HPLC system (Menarini 8140; Menarini Diagnostics, Wokingham, UK). Total cholesterol and total triglycerides were estimated using enzymatic methods (Boehringer-Mannheim, Mannheim, Germany). Lowdensity lipoprotein cholesterol was calculated using the Equation 3/4 (total cholesterol2high-density lipoprotein cholesterol) mmol/L described by de Cordova (20) . Urinary albumin and creatinine were measured by immunoturbidimetry (Cobas Fara, Roche Diagnostics, Lewes, UK) and the Jaffe rate reaction methods, respectively.
Plasma LOOH concentrations (range in nondiabetic subjects, 0.22 to 6.22 mmol/L) was measured by ferrous oxidation-xylenol orange assay in conjunction with the triphenylphosphine method (21) . The interassay and intra-assay coefficients of variation of the ferrous oxidation-xylenol orange assay are ,5% and ,6%, respectively. Plasma a-tocopherol concentrations was measured by HPLC (Menarini 8140, Wokingham, UK) as previously described (17) , and corrected for lipid profile with interassay and intra-assay coefficients of variation of 3%. Total monocyte and platelet counts were measured in whole venous blood (Advia 120, Bayer, Basingstoke, UK).
Cell culture
To measure cytokine production, whole blood cell cultures were incubated in triplicate with or without lipopolysaccharide (LPS) (25 mg/mL) to activate monocytes (22) . The interassay and intra-assay coefficients of variation for VEGF were 6% and 8% respectively. Concentration of the main circulating 165 amino acid VEGF-A isoform in culture supernatants was determined using an enzyme-linked immunosorbent assay kit, according to the manufacturer's protocol (R&D Systems Ltd, Abingdon, UK).
Statistics
Analyses were performed using Stata 14.2 (Stata Corp, TX). Continuous variables were compared using parametric or nonparametric tests according to their distribution. Categorical variables were compared using the x 2 or Fisher exact tests. Variables with skewed distribution were log-transformed before analyses. At an alpha of 0.05, the study had 98% power to detect a 16 pg/mL increase in LPS-stimulated VEGF. The multivariate model was based upon inputting those variables that were significantly different between the groups and/or of biological relevance to VEGF release. All tests were two-tailed and a P value ,0.05 was accepted as being statistically significant.
Results
The African-Caribbean and white groups had similar chronological age, BMI, systolic and diastolic blood pressures, fasting plasma glucose, glycated hemoglobin and cholesterols, and prevalence of retinopathy and microalbuminuria. There were more males in the African-Caribbean group and they tended to have a longer duration of diabetes in comparison with the white cohort, although the latter were more likely to have a positive smoking history and higher triglyceride concentrations, and monocyte and platelet counts (Table 1 ). There were no statistically significant differences in the proportions of patients in the African-Caribbean and white groups that were prescribed oral hypoglycemic agents (metformin and/ or sulphonylurea) or insulin (48 vs 53 or 36 vs 25%; P = 0.713) for blood glucose management, angiotensinconverting enzyme inhibitors, or angiotensin 2 receptor antagonists to lower blood pressure (44 vs 50%; P = 0.896) or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to lower cholesterol (43 vs 56%; P = 1.00).
LPS significantly increased VEGF concentrations from 61.8 (31.9) pg/mL to 78.4 (36.0) pg/mL; P , 0.001. Plasma LOOH and LPS-stimulated VEGF release corrected for monocyte count was significantly higher in African-Caribbean patients than white patients (Fig. 1) . Plasma LOOH correlated with VEGF concentration (r = 0.3; P = 0.04). Plasma a-tocopherol concentration was higher in a subset of a group (n = 19) of the white patients [40.3 (18. 3) vs 30.0 (9.6) mmol/L; P = 0.04] compared with group of African-Caribbean patients (n = 15). In multivariate analysis, current and previous history of smoking, female sex, white ethnicity (with marginal significance), and age all had negative b coefficients.
In this model, plasma LOOH remained the only statistically significant independent predictor ( Table 2 ).
Discussion
Our study has found that, in patients with T2DM, the production of VEGF from LPS stimulated whole blood cell cultures is higher and proportional to biochemical evidence of greater exposure to oxidative stress in patients of African-Caribbean compared with white origin. These findings are consistent with in vitro studies showing the induction of VEGF by LPS in monocytes and its upregulation by superoxide radical-generating systems in a time-and dose-dependent manner (23) . A circulating, cellular source of VEGF most notably appears to have an important role in the reparation of ischemic tissues. In animal models of myocardial ischemia, restoration of blood flow and preservation of function is associated with VEGF protein production and VEGF receptor gene expression (24, 25) . Studies in humans with myocardial infarction have shown that circulating VEGF is elevated and the VEGF gene expression increased during the acute phase of injury in both arterial smooth muscle cells and infiltrating macrophages (26, 27) . Furthermore, after acute cerebral infarction, elevation of circulating VEGF occurs in relation to the size of the lesion and the associated peripheral leucocytosis (28) . Leukocytes, which can be less populous in people of African origin, have the same relationship with low-grade inflammation and cardiometabolic risk seen in other ethnic groups with higher counts (29) . However, the differences in VEGF response we observed suggest that monocyte function may be modified by the higher levels of glucose-induced oxidative stress that occurs in the patients of AfricanCaribbean origin.
Monocyte-derived VEGF plays a key role in chronic vascular disease of significance to vasculopathy in diabetes (30) . Increasing evidence implicates increased tissue production of VEGF in the development of diabetic retinopathy. In this context, increased expression of VEGF in the retina and raised levels in the aqueous occur in relation to hypoxia, resulting in deleterious angiogenesis (31) (32) (33) . Circulating VEGF may be a marker of future renal disease in patients with diabetes (34) . The vascular permeability enhancing effects of VEGF may play a role in the rise in urinary albumin excretion. Albuminuria in turn mediates release of other proinflammatory cytokines (35) . In the evolution of diabetic nephropathy, monocytic infiltration is a feature of the development of tubulo-interstitial lesions; therefore, oxidative stress-induced VEGF could participate in the cascade of albuminuria, upregulation of chemoattractant molecules, increased monocyte attraction, and trafficking of proinflammatory molecules and fibrogenic cytokines such as transforming growth factor b1 within the kidney. In a streptozotocin, murine model of diabetes, increased podocyte VEGF signaling has been shown to significantly worsen the characteristic histological features of nephropathy (36) . Lee at al. reported that, in cultured murine podocytes, glucose-dependent increases in oxidative stress and VEGF could be completely ameliorated by different antioxidants (37) . Moreover, it has been reported that the renal histological changes associated with the db/db model of diabetes could be abrogated by neutralizing anti-VEGF antibody (38) . In addition, VEGF receptor tyrosine kinase inhibitor (SU5416) reduced albuminuria in the T2DM db/db mouse model (39) , supporting the involvement and interplay of increased oxidative stress with VEGF in the pathogenesis of diabetic nephropathy. An association between high circulating levels of VEGF and the oxidative effects of ferritin suggests that both have a role in the development of complications in patients with diabetes (40) . Also, a recently described association between advanced chronic kidney disease and VEGF implies that it may also have a role in renal disease progression (41) .
In our study, it would appear that the oxidative stress that determined the VEGF response to the inflammatory stimulus may be a proxy for ethnic origin. However, exposure to hyperglycemia is a possible explanation of the differences in redox status between the groups(42). Duration of diabetes was significantly longer in univariate analysis in the African-Caribbean group that, however, failed to reach statistical significance as independent predictor in multivariate analysis. Dietary factors could be relevant, and it is notable that a survey from the United States suggests that 40% of minority ethnic groups with diabetes have a deficient micronutrient intake, including vitamin E (43) . A limitation of our study was that we did not collect dietary details from our cohort so we were not able to determine whether the differences in oxidative stress between the groups were related to the intake of vitamin E. In summary, we show that a variation in VEGF production by activated, proinflammatory cells, is related to ambient oxidative stress. Infiltrating monocytes contribute to renal disease and these findings may have relevance to differing susceptibility to ESRD. Further clinical studies are required to examine the role of circulating monocyte VEGF production in the renal complications of diabetes. 
